Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) has integrated its respiratory diagnostic app with Coviu’s telehealth platform
- This fusion will allow clinicians using Coviu’s platform to perform a remote respiratory assessment
- ResApp and Coviu have signed a binding commercial term sheet and have agreed upon a per-test fee between $5 and $10 for patients using the respiratory app
- The agreement covers two years, with the option to extend
- ResApp is up 39.3 per cent on the market this morning, trading at 19.5¢ apiece
ResApp Health (RAP) has integrated its respiratory diagnostic app with Coviu’s telehealth platform.
This integration will allow clinicians using Coviu’s platform to perform a remote respiratory assessment using ResApp’s diagnostic test.
ResAPPDx-EU is a software application that is used to diagnose the most common respiratory diseases. The software uses machine learning algorithms that analyse a patient’s cough sounds to diagnose lower respiratory diseases such as pneumonia and asthma.
Coviu is Australia’s leading telehealth software company and a spinout of CSIRO’s Data61, offering a video consultation software to healthcare businesses. Coviu’s platform makes it easy for healthcare providers to offer their services directly to patients via video consultation.
ResApp and Coviu have signed a binding commercial term sheet and have agreed upon a per-test fee between $5 and $10 for the use of ResAPPDx-EU.
The agreement covers two years, with the option to extend.
COVID-19
The COVID-19 pandemic has put many healthcare workers at risk of contracting the highly contagious disease as they come into contact with patients. In fact, even patients who suspect they have the virus but are suffering from another respiratory condition, are also at risk if they present at physical clinics.
As a result, there’s been a further emphasis on the provision of telehealth services across Australia.
“In response to the COVID-19 crisis, the federal government has announced
that from today, Medicare will reimburse all telehealth consultations, giving every Australian the opportunity to consult with their doctor from the comfort and safety of their own home,” Coviu’s CEO and co-founder Dr Silvia Pfeiffer said.
“By using ResAppDx-EU inside our telehealth platform, clinicians can make more informed decisions when triaging the many patients who present with respiratory symptoms, which is especially important as the COVID-19 pandemic starts to coincide with the winter flu season,” she added.
ResApp is up 39.3 per cent on the market this morning, trading at 19.5¢ apiece at 11:20 am AEDT.
